Akari Therapeutics enters preclinical ADC research collaboration with Whitehawk Therapeutics
AKTX•Study roles and next steps
Akari will lead study design, execution, and evaluation, while both companies will jointly review results to guide potential broader development talks.
The collaboration starts immediately, and interim data updates are expected as the studies progress.
Preclinical collaboration on dual-payload ADCs
Akari Therapeutics entered a strategic research collaboration with Whitehawk Therapeutics to run preclinical studies on dual-payload ADCs.
Work will test Akari’s PH1 RNA-splicing payload in combination with Whitehawk’s topoisomerase I inhibitor ADC platform for compatibility and synergy.
